Key clinical point: In real-world settings, candesartan showed benefit as a preventive treatment for migraine with a 50% responder rate, similar to that observed in previous trials.
Major finding: Candesartan significantly reduced the number of headache days per month compared with baseline at weeks 8-12 (−4.3 days) and 20-24 (−4.7 days; both P less than .001). By weeks 8-12 and 20-24, 50% response was observed in 32.5% and 31.7% of patients, respectively. Common adverse events were light-headedness (5.0%), hypotension (4.2%), sleepiness (0.8%), and asthenia (0.8%).
Study details: The data come from a retrospective cohort study of 120 patients with chronic or episodic migraine who received candesartan between April 2008 and February 2019.
Disclosures: The study was a dissertation project supported by Junta de Castilla y León (Spain) and the European Social Fund. The authors declared no conflicts of interest.
Source: Sánchez-Rodríguez C et al. Sci Rep. 2021 Feb 15. doi: 10.1038/s41598-021-83508-2 .